Aptorum Group Limited Class A Stock

$0.94

1.27% yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

KYG6096M1069

Symbol

APM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Aptorum Group Limited Class A Stock price

$0.94

-31.66 97.11% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+0.01 1.28%

ISIN

KYG6096M1069

Symbol

APM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$6.7m

Enterprise Value

$9.2m

Net debt

$2.4m

Cash

$870.0k

Shares outstanding

5.6m

Valuation (TTM | estimate)

P/E

negative | 0.0

P/S

- | 0.0

EV/Sales

- | 0.1

EV/FCF

negative

P/B

0.3

Financial Health

Equity Ratio

131.0%

Return on Equity

-20.2%

ROCE

-31.1%

ROIC

Debt/Equity

0.2

Financials (TTM | estimate)

Revenue

$0.0 | $146.8m

EBITDA

$-3.4m | $15.0m

EBIT

$-3.7m | $114.5m

Net Income

$-4.3m | $334.3m

Free Cash Flow

$-1.2m

Growth (TTM | estimate)

Revenue

-100.0% | -

EBITDA

61.6% | 856.2%

EBIT

63.3% | 5,213.0%

Net Income

-51.4% | 7,929.0%

Free Cash Flow

84.6%

EPS

$-0.8

FCF per Share

$-0.2

Short interest

2.5%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Aptorum Group Limited Class A Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Aptorum Group Limited Class A forecast:

5x Buy

83%

1x Hold

17%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Aptorum Group Limited Class A forecast:

Buy

83%

Hold

17%

Analyst Estimates with Stock Price Targets

Financial data from Aptorum Group Limited Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	1.47 1.47	67% 67% -
- Research and Development Expense	1.82 1.82	50% 50% -
EBITDA	-3.41 -3.41	62% 62% -
- Depreciation and Amortization	0.26 0.26	77% 77% -
EBIT (Operating Income) EBIT	-3.67 -3.67	63% 63% -
Net Profit	-4.27 -4.27	51% 51% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aptorum Group Limited Class A Stock News

Neutral

GlobeNewsWire

●

3 months ago

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

Neutral

Business Wire

●

6 months ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

BELLEVUE, Wash.--(BUSINESS WIRE)--Synology launches the ActiveProtect series a unified enterprise backup solution set to disrupt the current data backup market.

Company Profile

Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.

Head office	Cayman Islands
CEO	Ian Huen
Employees	3
Founded	2010
Website	www.aptorumgroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now